Curie Oncology
Some information on this page may be available only to Healthcare Professionals. Please

About

Helmed by leading Medical Oncologists in Gastrointestinal, Hepatobiliary and Gynecological cancers, Curie Oncology provides personalised cancer services with access to state of the art cancer therapies in Singapore. Curie Oncology has a strong team that offers close attention and care for patients on active treatments and takes pride in being responsive to patients’ needs at all times.

The team at Curie Oncology is also a practice leader with its offering of remote second opinion consultants to Oncologists and patients in the region.

*Oncologists who are keen to collaborate with the Curie team may contact them via the contact link provided.

Oncology services

General Oncology Services:

Laboratory

Genomic testing services

Hereditary cancer screening

Second opinion consultation

Oncology treatments:

Chemotherapy

Precision medicine therapies

Immuno-oncologic therapy

Common tumour types seen include:

Gynaecological Cancers: Ovarian, Endometrial, Cervical

Gastrointestinal Cancers: Colorectal, Stomach, Hepatobiliary

Pancreas, Peritoneal, Anal

Breast, Uterine sarcoma, Germ cell tomours

and other cancers.

Branches

2

Curie Oncology (Novena)

38 Irrawaddy Road, #08-21 Mount Elizabeth Novena Medical Centre, Singapore 329563

Mon—Fri: 8:30 AM — 5:30 PM

Sat: 8:30 AM — 12:30 PM

Closed on Sunday and Public Holidays

Photos

Photo of Curie Oncology (Novena)
Photo of Curie Oncology (Novena)

Curie Oncology (Farrer)

1 Farrer Park Station Road, #10-05/06/07, Singapore 217562

Mon—Fri: 8:30 AM — 5:30 PM

Sat: 8:30 AM — 12:30 PM

Closed on Sunday and Public Holidays

Photos

Photo of Curie Oncology (Farrer)
Photo of Curie Oncology (Farrer)

Ongoing trials at Curie Oncology

6 trials shown

A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study

The study conducted on cancer patients is designed to test safety and efficacy of limb hypothermia in cancer patients using the new Paxman Limb Cryocompression System (PLCS). Ultim

Study number:
NCT05606068
Cohorts:
1
Study phase:
N/A
Overall status:
Not yet recruiting
Study type:
Chemotherapy, Supportive interventions

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally re

Study number:
NCT05374512
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Chemotherapy

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-98621

Study number:
NCT05328908
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy, Chemotherapy

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. Th

Study number:
NCT05152147
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy, Chemotherapy, Biomarker

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with niv

Study number:
NCT04785820
Cohorts:
1
Study phase:
2
Overall status:
Recruiting
Study type:
Immunotherapy

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domva

Study number:
NCT04262856
Cohorts:
1
Study phase:
2
Overall status:
Active, not recruiting
Study type:
Immunotherapy, Targeted therapy, Biomarker